QGEN vs. TECH, RGEN, EXEL, PCVX, RVMD, NBIX, IBRX, HALO, CRSP, and KRYS
Should you be buying Qiagen stock or one of its competitors? The main competitors of Qiagen include Bio-Techne (TECH), Repligen (RGEN), Exelixis (EXEL), Vaxcyte (PCVX), Revolution Medicines (RVMD), Neurocrine Biosciences (NBIX), ImmunityBio (IBRX), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), and Krystal Biotech (KRYS). These companies are all part of the "biological products, except diagnostic" industry.
Qiagen (NYSE:QGEN) and Bio-Techne (NASDAQ:TECH) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, community ranking, valuation and earnings.
Bio-Techne received 143 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 62.48% of users gave Bio-Techne an outperform vote while only 60.79% of users gave Qiagen an outperform vote.
In the previous week, Qiagen had 8 more articles in the media than Bio-Techne. MarketBeat recorded 38 mentions for Qiagen and 30 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 0.66 beat Qiagen's score of 0.41 indicating that Bio-Techne is being referred to more favorably in the news media.
70.0% of Qiagen shares are owned by institutional investors. Comparatively, 99.0% of Bio-Techne shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 4.5% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Qiagen has higher revenue and earnings than Bio-Techne. Qiagen is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.
Qiagen presently has a consensus target price of $50.95, indicating a potential upside of 18.53%. Bio-Techne has a consensus target price of $80.50, indicating a potential upside of 4.15%. Given Qiagen's higher possible upside, research analysts clearly believe Qiagen is more favorable than Bio-Techne.
Bio-Techne has a net margin of 17.59% compared to Qiagen's net margin of 17.38%. Bio-Techne's return on equity of 13.60% beat Qiagen's return on equity.
Qiagen has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.
Summary
Bio-Techne beats Qiagen on 12 of the 18 factors compared between the two stocks.
Get Qiagen News Delivered to You Automatically
Sign up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
